On March 15, 2022, the OI Foundation spoke with Dr. Brendan Lee, Principal Investigator for the Brittle Bone Disease Consortium (BBDC). In this interview, they discussed new drugs being studied to treat osteogenesis imperfecta, and the drug development process. Watch the session recording below, or click here to view the recording on YouTube.
This session is the fifth in a series meant to demystify and contextualize medical research from the Brittle Bone Disorders Consortium (BBDC). The BBDC is a multicenter initiative that focuses on understanding and providing better treatment options for osteogenesis imperfecta. The previous BBDC research updates can be viewed here
As a partner of the OIF, the BBDC has 3 major goals:
- Gain a better understanding of all genetic forms of OI
- Expand treatment options for those with OI
- Help guide the next generation of physicians and scientists.
This series is intended for anyone who wants to learn more about OI medical research. We hope you will attend a future session!
New study results on drug treatment for OI published in Journal of Clinical Investigation
The study, “Targeting transforming growth factor- β (TGF-β) for treatment of osteogenesis imperfecta” was led by OIF MAC Member Dr. Brendan Lee of Baylor College of Medicine. Click here to learn more about this study.